4569 — Kyorin Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00
- ¥105bn
- ¥107bn
- ¥113bn
- 63
- 60
- 75
- 79
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 113,620 | 109,983 | 102,904 | 105,534 | 113,270 |
Cost of Revenue | |||||
Gross Profit | 57,410 | 57,033 | 51,628 | 49,441 | 50,168 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 104,663 | 102,495 | 96,056 | 100,851 | 107,741 |
Operating Profit | 8,957 | 7,488 | 6,848 | 4,683 | 5,529 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 9,359 | 8,255 | 8,352 | 5,216 | 6,906 |
Provision for Income Taxes | |||||
Net Income After Taxes | 6,869 | 6,149 | 6,130 | 3,932 | 4,724 |
Net Income Before Extraordinary Items | |||||
Net Income | 6,869 | 6,149 | 6,130 | 3,932 | 4,724 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 6,869 | 6,149 | 6,130 | 3,932 | 4,723 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 106 | 108 | 88.8 | 73.2 | 77.7 |
Dividends per Share |